{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:49:20Z","timestamp":1793231360344,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12933-017-0658-8","type":"journal-article","created":{"date-parts":[[2018,1,4]],"date-time":"2018-01-04T12:25:50Z","timestamp":1515068750000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":350,"title":["The effect of dapagliflozin treatment on epicardial adipose tissue volume"],"prefix":"10.1186","volume":"17","author":[{"given":"Takao","family":"Sato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshifusa","family":"Aizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Yuasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Kishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Fuse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Kitazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahito","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Okabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,4]]},"reference":[{"key":"658_CR1","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1056\/NEJM199910073411501","volume":"341","author":"EE Calle","year":"1999","unstructured":"Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr. Body-mass index and mortality in a prospective cohort of US adults. N Engl J Med. 1999;341:1097\u2013105.","journal-title":"N Engl J Med"},{"key":"658_CR2","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJMoa055643","volume":"355","author":"KF Adams","year":"2006","unstructured":"Adams KF, Schatzkin A, Harris TB, Kipnis V, Mouw T, Ballard-Barbash R, Hollenbeck A, Leitzmann MF. Overweight, obesity, and mortality in a large prospective cohort of persons 50\u201371\u00a0years old. N Engl J Med. 2006;355:763\u201378.","journal-title":"N Engl J Med"},{"key":"658_CR3","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1749-6632.1999.tb07793.x","volume":"892","author":"Y Matsuzawa","year":"1999","unstructured":"Matsuzawa Y, Funahashi T, Nakamura T. Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. Ann NY Acad Sci. 1999;892:146\u201354.","journal-title":"Ann NY Acad Sci"},{"key":"658_CR4","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jacc.2011.01.048","volume":"58","author":"Y Hirata","year":"2011","unstructured":"Hirata Y, Tabata M, Kurobe H, Motoki T, Akaike M, Nishio C, Higashida M, Mikasa H, Nakaya Y, Takanashi S, Igarashi T, Kitagawa T, Sata M. Coronary atherosclerosis is associated with macrophage polarization in epicardial adipose tissue. J Am Coll Cardiol. 2011;58:248\u201355.","journal-title":"J Am Coll Cardiol"},{"key":"658_CR5","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1161\/ATVBAHA.112.300829","volume":"33","author":"M Shimabukuro","year":"2013","unstructured":"Shimabukuro M, Hirata Y, Tabata M, Dagvasumberel M, Sato H, Kurobe H, Fukuda D, Soeki T, Kitagawa T, Takanashi S, Sata M. Epicardial adipose tissue volume and adipocytokine imbalance are strongly linked to human coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 2013;33:1077\u201384.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"658_CR6","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1536\/ihj.52.139","volume":"52","author":"Y Hirata","year":"2011","unstructured":"Hirata Y, Kurobe H, Akaike M, Chikugo F, Hori T, Bando Y, Nishio C, Higashida M, Nakaya Y, Kitagawa T, Sata M. Enhanced inflammation in epicardial fat in patients with coronary artery disease. Int Heart J. 2011;52:139\u201342.","journal-title":"Int Heart J."},{"key":"658_CR7","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1161\/ATVBAHA.108.182907","volume":"29","author":"K Cl\u00e9ment","year":"2009","unstructured":"Cl\u00e9ment K, Basdevant A, Dutour A. Weight of pericardial fat on coronaropathy. Arterioscler Thromb Vasc Biol. 2009;29:615\u20136.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"658_CR8","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1253\/circj.71.536","volume":"71","author":"JW Jeong","year":"2007","unstructured":"Jeong JW, Jeong MH, Yun KH, Oh SK, Park EM, Kim YK, Rhee SJ, Lee EM, Lee J, Yoo NJ, Kim NH, Park JC. Echocardiographic epicardial fat thickness and coronary artery disease. Circ J. 2007;71:536\u20139.","journal-title":"Circ J"},{"key":"658_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-2840-5-1","volume":"5","author":"AR Baker","year":"2006","unstructured":"Baker AR, Silva NF, Quinn DW, Harte AL, Pagano D, Bonser RS, Kumar S, McTernan PG. Human epicardial adipose tissue expresses a pathogenic profile of adipocytokines in patients with cardiovascular disease. Cardiovasc Diabetol. 2006;5:1.","journal-title":"Cardiovasc Diabetol."},{"key":"658_CR10","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s40268-016-0137-9","volume":"16","author":"A Okamoto","year":"2016","unstructured":"Okamoto A, Yokokawa H, Sanada H, Naito T. Changes in levels of biomarkers associated with adipocyte function and insulin and glucagon kinetics during treatment with dapagliflozin among obese type 2 diabetes mellitus patients. Drugs RD. 2016;16:255\u201361.","journal-title":"Drugs RD."},{"key":"658_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0146337","author":"Y Honda","year":"2016","unstructured":"Honda Y, Imajo K, Kato T, Kessoku T, Ogawa Y, Tomeno W, Kato S, Mawatari H, Fujita K, Yoneda M, Saito S, Nakajima A. The selective SGLT2 inhibitor ipragliflozin has therapeutic effect on nonalcoholic steatohepatitis in mice. PLoS ONE. 2016. https:\/\/doi.org\/10.1371\/journal.pone.0146337.","journal-title":"PLoS ONE"},{"key":"658_CR12","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1210\/jc.2011-2260","volume":"97","author":"J Bolinder","year":"2012","unstructured":"Bolinder J, Ljunggren \u00d6, Kullberg J, Johansson L, Wilding J, Langkilde AM, Sugg J, Parikh S. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97:1020\u201331.","journal-title":"J Clin Endocrinol Metab"},{"key":"658_CR13","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC. Inzucchi SE;\u00a0EMPA-REG OUTCOME investigators. empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u201328.","journal-title":"N Engl J Med"},{"key":"658_CR14","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/dom.12680","volume":"18","author":"A Dutour","year":"2016","unstructured":"Dutour A, Abdesselam I, Ancel P, Kober F, Mrad G, Darmon P, Ronsin O, Pradel V, Lesavre N, Martin JC, Jacquier A, Lefur Y, Bernard M, Gaborit B. Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: prospective randomized clinical trial using magnetic resonance imaging and spectroscopy. Diabetes Obes Metab. 2016;18:882\u201391.","journal-title":"Diabetes Obes Metab"},{"key":"658_CR15","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(09)60619-X","volume":"373","author":"AG Tab\u00e1k","year":"2009","unstructured":"Tab\u00e1k AG, Jokela M, Akbaraly TN, Brunner EJ, Kivim\u00e4ki M, Witte DR. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet. 2009;373:2215\u201321.","journal-title":"Lancet"},{"key":"658_CR16","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.5551\/jat.23390","volume":"21","author":"T Sato","year":"2014","unstructured":"Sato T, Kameyama T, Ohori T, Matsuki A, Inoue H. Effects of eicosapentaenoic acid treatment on epicardial and abdominal visceral adipose tissue volumes in patients with coronary artery disease. J Atheroscler Thromb. 2014;21:1031\u201343.","journal-title":"J Atheroscler Thromb."},{"key":"658_CR17","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1161\/ATVBAHA.111.241984","volume":"32","author":"ED Abel","year":"2012","unstructured":"Abel ED, O\u2019Shea KM, Ramasamy R. Insulin resistance: metabolic mechanisms and consequences in the heart. Arterioscler Thromb Vasc Biol. 2012;32:2068\u201376.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"658_CR18","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1172\/JCI29881","volume":"117","author":"CN Lumeng","year":"2007","unstructured":"Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007;117:175\u201384.","journal-title":"J Clin Invest."},{"key":"658_CR19","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1172\/JCI200319246","volume":"112","author":"SP Weisberg","year":"2003","unstructured":"Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112:1796\u2013808.","journal-title":"J Clin Invest."},{"key":"658_CR20","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00592-014-0655-2","volume":"52","author":"C Zhang","year":"2015","unstructured":"Zhang C, Luo H, Gao F, Zhang CT, Zhang R. A reduction in both visceral and subcutaneous fats contributes to increased adiponectin by lifestyle intervention in the diabetes prevention program. Acta Diabetol. 2015;52:625\u20138.","journal-title":"Acta Diabetol"},{"key":"658_CR21","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.dsx.2014.09.003","volume":"8","author":"GD Miller","year":"2014","unstructured":"Miller GD, Isom S, Morgan TM, Vitolins MZ, Blackwell C, Brosnihan KB, Diz DI, Katula J, Goff D. Effects of a community-based weight loss intervention on adipose tissue circulating factors. Diabetes Metab Syndr. 2014;8:205\u201311.","journal-title":"Diabetes Metab Syndr."},{"key":"658_CR22","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ebiom.2017.05.028","volume":"20","author":"L Xu","year":"2017","unstructured":"Xu L, Nagata N, Nagashimada M, Zhuge F, Ni Y, Chen G, Mayoux E, Kaneko S, Ota T. SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice. EBioMedicine. 2017;20:137\u201349.","journal-title":"EBioMedicine."},{"key":"658_CR23","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/oby.2008.251","volume":"16","author":"G Iacobellis","year":"2008","unstructured":"Iacobellis G, Singh N, Wharton S, Sharma AM. Substantial changes in epicardial fat thickness after weight loss in severely obese subjects. Obesity. 2008;16:1693\u20137.","journal-title":"Obesity."},{"key":"658_CR24","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12933-017-0528-4","volume":"16","author":"N Gonz\u00e1lez","year":"2017","unstructured":"Gonz\u00e1lez N, Moreno-Villegas Z, Gonz\u00e1lez-Bris A, Egido J, Lorenzo \u00d3. Regulation of visceral and epicardial adipose tissue for preventing cardiovascular injuries associated to obesity and diabetes. Cardiovasc Diabetol. 2017;16:44.","journal-title":"Cardiovasc Diabetol."},{"key":"658_CR25","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12933-017-0516-8","volume":"16","author":"R Bouchi","year":"2017","unstructured":"Bouchi R, Terashima M, Sasahara Y, Asakawa M, Fukuda T, Takeuchi T, Nakano Y, Murakami M, Minami I, Izumiyama H, Hashimoto K, Yoshimoto T, Ogawa Y. Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study. Cardiovasc Diabetol. 2017;16:32.","journal-title":"Cardiovasc Diabetol."},{"key":"658_CR26","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s13300-017-0279-y","volume":"8","author":"T Fukuda","year":"2017","unstructured":"Fukuda T, Bouchi R, Terashima M, Sasahara Y, Asakawa M, Takeuchi T, Nakano Y, Murakami M, Minami I, Izumiyama H, Hashimoto K, Yoshimoto T, Ogawa Y. Ipragliflozin reduces epicardial fat accumulation in non-obese type 2 diabetic patients with visceral obesity: a pilot study. Diabetes Ther. 2017;8:851\u201361.","journal-title":"Diabetes Ther."},{"key":"658_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvx186","author":"E D\u00edaz-Rodr\u00edguez","year":"2017","unstructured":"D\u00edaz-Rodr\u00edguez E, Agra RM, Fern\u00e1ndez \u00c1L, Adrio B, Garc\u00eda-Caballero T, Gonz\u00e1lez-Juanatey JR, Eiras S. Novel effects of dapagliflozin on epicardial adipose tissue with insulin resistance, high levels of inflammatory chemokines production and low differentiation ability. Cardiovasc Res. 2017. https:\/\/doi.org\/10.1093\/cvr\/cvx186.","journal-title":"Cardiovasc Res"},{"key":"658_CR28","doi-asserted-by":"publisher","first-page":"e0151511","DOI":"10.1371\/journal.pone.0151511","volume":"11","author":"C Komiya","year":"2016","unstructured":"Komiya C, Tsuchiya K, Shiba K, Miyachi Y, Furuke S, Shimazu N, Yamaguchi S, Kanno K, Ogawa Y. Ipragliflozin improves hepatic steatosis in obese mice and liver dysfunction in type 2 diabetic patients irrespective of body weight reduction. PLoS ONE. 2016;11:e0151511. https:\/\/doi.org\/10.1371\/journal.pone.0151511.","journal-title":"PLoS ONE"},{"key":"658_CR29","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12933-016-0356-y","volume":"15","author":"C Sonesson","year":"2016","unstructured":"Sonesson C, Johansson PA, Johnsson E, Gause-Nilsson I. Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis. Cardiovasc Diabetol. 2016;15:37.","journal-title":"Cardiovasc Diabetol."},{"key":"658_CR30","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1177\/1479164114559852","volume":"12","author":"SE Inzucchi","year":"2015","unstructured":"Inzucchi SE, Zinman B, Wanner C, Ferrari R, Fitchett D, Hantel S, Espadero RM, Woerle HJ, Broedl UC, Johansen OE. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res. 2015;12:90\u2013100.","journal-title":"Diab Vasc Dis Res."},{"key":"658_CR31","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12933-016-0491-5","volume":"16","author":"T Hayashi","year":"2017","unstructured":"Hayashi T, Fukui T, Nakanishi N, Yamamoto S, Tomoyasu M, Osamura A, Ohara M, Yamamoto T, Ito Y, Hirano T. Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin. Cardiovasc Diabetol. 2017;16:8.","journal-title":"Cardiovasc Diabetol."},{"key":"658_CR32","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1161\/01.ATV.0000154144.73236.f4","volume":"25","author":"AC St-Pierre","year":"2005","unstructured":"St-Pierre AC, Cantin B, Dagenais GR, Mauri\u00e8ge P, Bernard PM, Despr\u00e9s JP, Lamarche B. Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Qu\u00e9bec Cardiovascular Study. Arterioscler Thromb Vasc Biol. 2005;25:553\u20139.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"658_CR33","doi-asserted-by":"crossref","first-page":"186","DOI":"10.5551\/jat.10.186","volume":"10","author":"C Maruyama","year":"2003","unstructured":"Maruyama C, Imamura K, Teramoto T. Assessment of LDL particle size by triglyceride\/HDL-cholesterol ratio in non-diabetic, healthy subjects without prominent hyperlipidemia. J Atheroscler Thromb. 2003;10:186\u201391.","journal-title":"J Atheroscler Thromb."},{"key":"658_CR34","doi-asserted-by":"crossref","first-page":"730","DOI":"10.2337\/dc10-2083","volume":"34","author":"HS Sacks","year":"2011","unstructured":"Sacks HS, Fain JN, Cheema P, Bahouth SW, Garrett E, Wolf RY, Wolford D, Samaha J. Inflammatory genes in epicardial fat contiguous with coronary atherosclerosis in the metabolic syndrome and type 2 diabetes: changes associated with pioglitazone. Diabetes Care. 2011;34:730\u20133.","journal-title":"Diabetes Care"},{"key":"658_CR35","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s12020-015-0710-y","volume":"51","author":"MM Lima-Martinez","year":"2016","unstructured":"Lima-Martinez MM, Paoli M, Rodney M, Balladares N, Contreras M, D\u2019Marco L, Iacobellis G. Effect of sitagliptin on epicardial fat thickness in subjects with type 2 diabetes and obesity: a pilot study. Endocrine. 2016;51:448\u201355.","journal-title":"Endocrine"},{"key":"658_CR36","unstructured":"Iacobellis G, Mohseni M, Bianco S. Liraglutide causes massive and rapid reduction of cardiac fat independent of weight loss in type 2 diabetes. In: The proceedings of 75th American Diabetes Association, Scientific Sessions, LBA-5785, Boston, USA, 2015."},{"key":"658_CR37","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/obr.12270","volume":"16","author":"SW Rabkin","year":"2015","unstructured":"Rabkin SW, Campbell H. Comparison of reducing epicardial fat by exercise, diet or bariatric surgery weight loss strategies: a systematic review and meta-analysis. Obes Rev. 2015;16:406\u201315.","journal-title":"Obes Rev"},{"key":"658_CR38","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nm.3828","volume":"21","author":"C Bonner","year":"2015","unstructured":"Bonner C, Kerr-Conte J, Gmyr V, Queniat G, Moerman E, Th\u00e9venet J, Beaucamps C, Delalleau N, Popescu I, Malaisse WJ, Sener A, Deprez B, Abderrahmani A, Staels B, Pattou F. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015;21:512\u20137.","journal-title":"Nat Med"},{"key":"658_CR39","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/nature05488","volume":"444","author":"JP Despres","year":"2006","unstructured":"Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006;444:881\u20137.","journal-title":"Nature"},{"key":"658_CR40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mam.2012.10.001","volume":"34","author":"MJ Lee","year":"2013","unstructured":"Lee MJ, Wu Y, Fried SK. Adipose tissue heterogeneity: implication of depot differences in adipose tissue for obesity. Mol Aspects Med. 2013;34:1\u201311.","journal-title":"Mol Aspects Med"},{"key":"658_CR41","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4093\/dmj.2015.39.5.405","volume":"39","author":"DK Song","year":"2015","unstructured":"Song DK, Hong YS, Lee H, Oh JY, Sung YA, Kim Y. Increased epicardial adipose tissue thickness in type 2 diabetes mellitus and obesity. Diabetes Metab J. 2015;39:405\u201313.","journal-title":"Diabetes Metab J."},{"key":"658_CR42","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.ahj.2007.03.019","volume":"153","author":"HS Sacks","year":"2007","unstructured":"Sacks HS, Fain JN. Human epicardial adipose tissue: a review. Am Heart J. 2007;153:907\u201317.","journal-title":"Am Heart J"},{"key":"658_CR43","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1161\/01.CIR.0000099542.57313.C5","volume":"108","author":"T Mazurek","year":"2003","unstructured":"Mazurek T, Zhang L, Zalewski A, Mannion JD, Diehl JT, Arafat H, Sarov-Blat L, O\u2019Brien S, Keiper EA, Johnson AG, Martin J, Goldstein BJ, Shi Y. Human epicardial adipose tissue is a source of inflammatory mediators. Circulation. 2003;108:2460\u20136.","journal-title":"Circulation"},{"key":"658_CR44","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jacc.2012.11.062","volume":"61","author":"AA Mahabadi","year":"2013","unstructured":"Mahabadi AA, Berg MH, Lehmann N, K\u00e4lsch H, Bauer M, Kara K, Dragano N, Moebus S, J\u00f6ckel KH, Erbel R, M\u00f6hlenkamp S. Association of epicardial fat with cardiovascular risk factors and incident myocardial infarction in the general population: the Heinz Nixdorf Recall Study. J Am Coll Cardiol. 2013;61:1388\u201395.","journal-title":"J Am Coll Cardiol"},{"key":"658_CR45","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/nm1295","volume":"11","author":"R Shibata","year":"2005","unstructured":"Shibata R, Sato K, Pimentel DR, Takemura Y, Kihara S, Ohashi K, Funahashi T, Ouchi N, Walsh K. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med. 2005;11:1096\u2013103.","journal-title":"Nat Med"},{"key":"658_CR46","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1161\/01.CIR.0000042707.50032.19","volume":"106","author":"Y Okamoto","year":"2002","unstructured":"Okamoto Y, Kihara S, Ouchi N, Nishida M, Arita Y, Kumada M, Ohashi K, Sakai N, Shimomura I, Kobayashi H, Terasaka N, Inaba T, Funahashi T, Matsuzawa Y. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2002;106:2767\u201370.","journal-title":"Circulation"},{"issue":"382","key":"658_CR47","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0140-6736(13)60683-2","volume":"14","author":"WT Cefalu","year":"2013","unstructured":"Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J, Balis DA, Canovatchel W, Meininger G. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52\u00a0week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;14(382):941\u201350.","journal-title":"Lancet"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-017-0658-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,4]],"date-time":"2018-01-04T12:26:04Z","timestamp":1515068764000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-017-0658-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,4]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["658"],"URL":"https:\/\/doi.org\/10.1186\/s12933-017-0658-8","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,4]]},"article-number":"6"}}